User:Mr. Ibrahem/Deferasirox

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Deferasirox
Clinical data
Pronunciationde FER a sir ox
Trade namesExjade, Jadenu, others
Other namesCGP-72670, ICL-670A, IC L670
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth
Drug classIron chelator[1]
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability70%
Protein binding99%
MetabolismLiver glucuronidation
Elimination half-life8 to 16 hours
ExcretionFecal (84%) and renal (8%)
Identifiers
  • 4-(3,5-Bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid
Chemical and physical data
FormulaC21H15N3O4
Molar mass373.368 g·mol−1
3D model (JSmol)
Density1.4±0.1 g/cm3 [2]
  • OC(=O)c1ccc(cc1)n2nc(nc2c3ccccc3O)c4ccccc4O
  • InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28) checkY
  • Key:BOFQWVMAQOTZIW-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Deferasirox, sold under the brand name Exjade among others, is a medication used for chronic iron overload in those receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.[3] It is generally only when deferoxamine is not sufficient.[3] It is taken by mouth.[4]

Common side effects include kidney problems, nausea, diarrhea, heart burn, rash, itchiness, and liver problems.[3] Other side effects may include metabolic acidosis, bone marrow suppression, and gastrointestinal bleeding.[3][1] It should not be used in people with kidney problems.[1] It is believed to be harmful in pregnancy.[5] It is an iron chelator.[1]

Deferasirox was approved for medical use in the United States in 2005 and Europe in 2006.[6][3] It is on the World Health Organization's List of Essential Medicines.[7] In the United Kingdom a month at a dose of 360 mg per day costs the NHS about £500 as of 2021.[4] In the United States this amount costs about 190 USD.[8] Generic versions were approved in 2020.[9]

References[edit]

  1. ^ a b c d "DailyMed - DEFERASIROX- deferasirox tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 11 January 2022. Retrieved 21 December 2021.
  2. ^ "Material Safety Data Sheet (MSDS): Deferasirox". ChemSrc. 2018. Archived from the original on 2017-06-12. Retrieved 2021-06-28.
  3. ^ a b c d e f g "Exjade". Archived from the original on 16 September 2021. Retrieved 21 December 2021.
  4. ^ a b c BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1074. ISBN 978-0857114105.
  5. ^ "Deferasirox Use During Pregnancy". Drugs.com. Archived from the original on 29 November 2020. Retrieved 21 December 2021.
  6. ^ "Deferasirox Monograph for Professionals". Drugs.com. Archived from the original on 15 August 2020. Retrieved 21 December 2021.
  7. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  8. ^ "Deferasirox Prices and Deferasirox Coupons - GoodRx". GoodRx. Retrieved 21 December 2021.
  9. ^ "Drugs@FDA: FDA-Approved Drugs". U.S. Food and Drug Administration. Archived from the original on 19 October 2020. Retrieved 15 August 2020.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Deferasirox&oldid=1208884541"